SciELO - Scientific Electronic Library Online

 
vol.29 issue4Percutaneous mitral balloon valvuloplasty: clinical and echocardiographic factors associated with success in a Tertiary-Care Hospital in Mexico author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista mexicana de cardiología

Print version ISSN 0188-2198

Abstract

SANTIBANEZ VELAZQUEZ, Martin; ARREGUIN PORRAS, Juan Francisco; GARCIA HERNANDEZ, Ernesto  and  MEDINA GARCIA, Gabriela. Contrast induced nephropathy in patients with primary percutaneous coronary intervention with or without metabolic syndrome. Rev. Mex. Cardiol [online]. 2018, vol.29, n.4, pp.152-158.  Epub Apr 25, 2022. ISSN 0188-2198.

Contrast induced nephropathy (CIN) is defined as the absolute increment of serum creatinine ≥ 0.5 mg/dL or an increment more than 25% of basal creatinine, without any other identified cause, within 48 hours after contrast media administration.

Objective:

Determine the CIN risk in patients with Acute Coronary Syndrome (ACS) with or without metabolic syndrome (MetS) treated with primary percutaneous coronary intervention (PCI).

Material and methods:

A prospective, observational, longitudinal and comparative study, in patients with ACS admitted to the Coronary Care Unit or Intensive Care Unit. PCI was performed with a serum creatinine (sCr) of ≤ 1.2 mg/dL prior intervention. Serum creatinine determinations were conducted 24-48 hours post PCI. The statistical test for analysis of free distribution quantitative variables was performed with Mann Whitney U test, and for qualitative variables Chi square test (χ2). Likelihood-ratio and confidence interval of 95% with p = 0.05.

Results:

420 patients with infarction code were studied, 323 men (76.9%), 97 women (23.1%), with ages between 56-70 years. They were divided into 2 groups: group A 176 (41.9%) with MetS and group B 244 (58%) without MetS. CIN was present in 43 patients (10.2%) group A and in 29 (6.9%) group B. RR: 2.05, CI 95% 1.33-3.15, p = 0.0012.

Conclusions:

MetS is a risk factor (RF) for the development of CIN in patients with ACS who undergo PCI. Therefore, this syndrome should be kept in mind for an early detection and prevention of the development of CIN.

Keywords : Acute coronary syndrome; metabolic syndrome; percutaneous coronary intervention; contrast-induced nephropathy.

        · abstract in Spanish     · text in English